tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2022 Nov 30;9(11)
fac554.
doi: 10.1093/ofid/ofac554. eCollection 2022 Nov.
Younger Children Develop Higher Effector Antibody Responses to SARS-CoV-2 Infection
Lisa Tomasi[SUP] 1 [/SUP], Anais Thiriard[SUP] 2 [/SUP], Leo Heyndrickx[SUP] 3 [/SUP], Daphnée Georges[SUP] 2 4 [/SUP], Sigi Van den Wijngaert[SUP] 5 [/SUP], Véronique Olislagers[SUP] 2 [/SUP], Shilpee Sharma[SUP] 2 [/SUP], André Matagne[SUP] 4 [/SUP], Margaret E Ackerman[SUP] 6 [/SUP], Kevin K Ariën[SUP] 3 7 [/SUP], Tessa Goetghebuer[SUP] 1 2 [/SUP], Arnaud Marchant[SUP] 2 [/SUP]
Affiliations
Abstract
Background: The basis of the less severe clinical presentation of coronavirus disease 2019 (COVID-19) in children as compared with adults remains incompletely understood. Studies have suggested that a more potent boosting of immunity to endemic common cold coronaviruses (HCoVs) may protect children.
Methods: To test this hypothesis, we conducted a detailed analysis of antibodies induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children aged 2 months to 14 years.
Results: Younger children had higher titers of antibodies to SARS-CoV-2 receptor binding domain (RBD), S1 but not S2 domain, and total spike (S) protein, higher avidity RBD immunoglobulin G, and higher titers of neutralizing and complement-activating antibodies as compared with older children. In contrast, older children had higher titers of antibodies to HCoVs, which correlated with antibodies to the SARS-CoV-2 S2 domain but not with neutralizing or complement-activating antibodies.
Conclusions: These results reveal a unique capacity of young children to develop effector antibody responses to SARS-CoV-2 infection independently of their immunity to HCoVs.
Keywords: COVID-19; SARS-CoV-2; antibodies; children; endemic coronaviruses.
. 2022 Nov 30;9(11)
fac554.doi: 10.1093/ofid/ofac554. eCollection 2022 Nov.
Younger Children Develop Higher Effector Antibody Responses to SARS-CoV-2 Infection
Lisa Tomasi[SUP] 1 [/SUP], Anais Thiriard[SUP] 2 [/SUP], Leo Heyndrickx[SUP] 3 [/SUP], Daphnée Georges[SUP] 2 4 [/SUP], Sigi Van den Wijngaert[SUP] 5 [/SUP], Véronique Olislagers[SUP] 2 [/SUP], Shilpee Sharma[SUP] 2 [/SUP], André Matagne[SUP] 4 [/SUP], Margaret E Ackerman[SUP] 6 [/SUP], Kevin K Ariën[SUP] 3 7 [/SUP], Tessa Goetghebuer[SUP] 1 2 [/SUP], Arnaud Marchant[SUP] 2 [/SUP]
Affiliations
- PMID: 36467295
- PMCID: PMC9709628
- DOI: 10.1093/ofid/ofac554
Abstract
Background: The basis of the less severe clinical presentation of coronavirus disease 2019 (COVID-19) in children as compared with adults remains incompletely understood. Studies have suggested that a more potent boosting of immunity to endemic common cold coronaviruses (HCoVs) may protect children.
Methods: To test this hypothesis, we conducted a detailed analysis of antibodies induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children aged 2 months to 14 years.
Results: Younger children had higher titers of antibodies to SARS-CoV-2 receptor binding domain (RBD), S1 but not S2 domain, and total spike (S) protein, higher avidity RBD immunoglobulin G, and higher titers of neutralizing and complement-activating antibodies as compared with older children. In contrast, older children had higher titers of antibodies to HCoVs, which correlated with antibodies to the SARS-CoV-2 S2 domain but not with neutralizing or complement-activating antibodies.
Conclusions: These results reveal a unique capacity of young children to develop effector antibody responses to SARS-CoV-2 infection independently of their immunity to HCoVs.
Keywords: COVID-19; SARS-CoV-2; antibodies; children; endemic coronaviruses.